Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!
Data: Axios/Ipsos survey; Chart: Axios Visuals

People who have survived a coronavirus infection say the experience made them take the pandemic more seriously, according to an Axios/Ipsos survey— the first to focus exclusively on people who have contracted the virus.

The big picture: A vocal group of White House officials, state officials and conservative pundits have argued for months that the virus simply is not that big a deal for the people who don’t die or become seriously ill. But that’s not how those patients themselves see it.

By the numbers: 54% of the coronavirus survivors in our survey said contracting the virus made them take it more seriously, compared to just 15% who now take it less seriously.

  • 63% said they’re likely to take a vaccine once it’s publicly available — 15 percentage points higher than the general population.

Key caveat: This survey covered 319 people who said they had tested positive for a coronavirus infection. That’s a relatively small sample, and it has a relatively large margin of error, at +/- 7.5 percentage points.

  • But it's still the first survey of its kind, and it provides valuable statistical insight, in big-picture terms, into the thoughts and feelings of the large and growing share of Americans who have been infected during this pandemic.

What they’re saying: “Even for a lot of people for whom it's supposed to be no big deal, it’s a pretty big deal,” said Ashish Jha, the dean of public health at Brown University. “That strikes me as saying something really meaningful about how serious the virus is for people who end up getting infected.”

Only 10% of respondents in this survey said they were hospitalized, an objective indication that most of them did not suffer the most severe illness.

  • Roughy 80% described their own symptoms as mild or moderate.

Those patients — the ones who don’t die or become gravely ill — are central to the “herd immunity” strategy advanced by some conservatives, including former Trump administration advisers Scott Atlas and Paul Alexander.

  • They argue that because COVID-19 kills a relatively small percentage of the people it infects, the U.S. should attempt to cordon off the most vulnerable people without worrying so much about the virus' continued spread throughout the rest of the population, or even encourage that spread, so that more people will develop natural immunity.
  • You hear some similar themes — even if I get it, I’ll be fine; it’s not that bad — from some people who reject masks, social distancing or other public-health guidelines.

But even though people who have had the virus may develop some level of immunity, the recovered patients in our survey were bullish on getting vaccinated — another indication that, to the people who know best what a mild infection really feels like, it doesn't feel so minor.

“There has been this mindset — really based on very little evidence — that if you're not 75 and over with lots of chronic diseases, it's just not a big deal,” Jha said. “And that mindset is wrong and destructive.”

Go deeper

Jan 30, 2021 - World

Science helps New Zealand avoid another coronavirus lockdown

New Zealand Prime Minister Jacinda Ardern (L) visits a lab at Auckland University in December. Photo: Phil Walter/Getty Images

New Zealand has avoided locking down for a second time over COVID-19 community cases because of a swift, science-led response.

Why it matters: The Health Ministry said in an email to Axios Friday there's "no evidence of community transmission" despite three people testing positive after leaving managed hotel isolation. That means Kiwis can continue to visit bars, restaurants and events as much of the world remains on lockdown.

Jan 29, 2021 - Health

WHO says most pregnant women can now receive coronavirus vaccine

A doctor administering Moderna's coronavirus vaccine at a university hospital in Essen, Germany, on Jan. 18. Photo: Lukas Schulze/Getty Images

The World Health Organization has altered its guidance for pregnant women who wish to receive the coronavirus vaccine, saying now that those at high risk of exposure to the COVID-19 or who have comorbidities that increase their risk of severe disease, may be vaccinated.

Why it matters: The WHO drew backlash for its previous guidance that did not recommend pregnant women be inoculated with vaccines made by Pfizer-BioNTech or Moderna, even though data indicated that pregnancy increased the risk of developing severe illness from the virus.

Jan 29, 2021 - World

EU grants conditional approval of AstraZeneca vaccine

Photo: Sunil Ghosh/Hindustan Times via Getty Images

The European Commission on Friday granted conditional approval of the Oxford-AstraZeneca coronavirus vaccine for people 18 years and older.

Why it matters: This is the third vaccine to receive approval from the commission, coming hours after the Emergency Medicines Agency recommended its authorization.